StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3018% below fair value
$4.34−0.22 (-4.82%)

Close on Nov 18, 2026Market cap $483.95MP/E –Yield –

Gyre Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Gyre Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$6.34M. For fiscal 2025 it was $1.01M. The highest annual figure on record is $138.30M in fiscal 2010.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.01M–
FY2024Dec 31, 2024-$3.64M-114.1%
FY2023Dec 31, 2023$25.89M+142.5%
FY2022Dec 31, 2022$10.68M–
FY2021Dec 31, 2021-$83.76M–
FY2020Dec 31, 2020-$55.05M–
FY2019Dec 31, 2019-$43.61M–
FY2018Dec 31, 2018-$28.55M–
FY2017Dec 31, 2017-$19.94M–
FY2016Dec 31, 2016-$18.47M–
FY2015Dec 31, 2015-$19.12M–
FY2014Dec 31, 2014-$6.39M–
FY2013Dec 31, 2013-$6.27M–
FY2012Dec 31, 2012-$64.24M–
FY2011Dec 31, 2011-$83.72M-160.5%
FY2010Dec 31, 2010$138.30M–
FY2009Dec 31, 2009-$24.27M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$3.98M–
Q2 FY2026Jun 30, 2026-$16.73M–
Q1 FY2026Mar 31, 2026$3.18M–
Q4 FY2025Dec 31, 2025$11.20M–
Q3 FY2025Sep 30, 2025-$2.58M-249.6%
Q2 FY2025Jun 30, 2025-$7.47M–
Q1 FY2025Mar 31, 2025-$129.00K-104.5%
Q4 FY2024Dec 31, 2024-$2.76M-182.1%
Q3 FY2024Sep 30, 2024$1.73M-77.2%
Q2 FY2024Jun 30, 2024-$5.49M-221.2%
Q1 FY2024Mar 31, 2024$2.88M-72.3%
Q4 FY2023Dec 31, 2023$3.36M-92.1%
Q3 FY2023Sep 30, 2023$7.58M–
Q2 FY2023Jun 30, 2023$4.53M–
Q1 FY2023Mar 31, 2023$10.42M–
Q4 FY2022Dec 31, 2022$42.30M–
Q3 FY2022Sep 30, 2022-$7.28M–
Q2 FY2022Jun 30, 2022-$12.29M–
Q1 FY2022Mar 31, 2022-$12.05M–
Q4 FY2021Dec 31, 2021-$17.68M–
Q3 FY2021Sep 30, 2021-$21.60M–
Q2 FY2021Jun 30, 2021-$20.12M–
Q1 FY2021Mar 31, 2021-$24.36M–
Q4 FY2020Dec 31, 2020-$22.11M–
Q3 FY2020Sep 30, 2020-$13.01M–
Q2 FY2020Jun 30, 2020-$15.14M–
Q1 FY2020Mar 31, 2020-$4.79M–
Q4 FY2019Dec 31, 2019-$8.09M–
Q3 FY2019Sep 30, 2019-$9.10M–
Q2 FY2019Jun 30, 2019-$11.47M–
Q1 FY2019Mar 31, 2019-$14.96M–
Q4 FY2018Dec 31, 2018-$9.01M–
Q3 FY2018Sep 30, 2018-$7.02M–
Q2 FY2018Jun 30, 2018-$7.41M–
Q1 FY2018Mar 31, 2018-$5.11M–
Q4 FY2017Dec 31, 2017-$6.32M–
Q3 FY2017Sep 30, 2017-$4.93M–
Q2 FY2017Jun 30, 2017-$4.40M–
Q1 FY2017Mar 31, 2017-$4.29M–
Q4 FY2016Dec 31, 2016-$4.98M–

More Gyre Therapeutics figures

See a number that looks wrong?